- Market Capitalization, $K 111,392,648
- Shares Outstanding, K 2,692,595
- Annual Sales, $ 43,783 M
- Annual Income, $ 7,382 M
- 60-Month Beta 0.74
- Price/Sales 2.53
- Price/Cash Flow 10.62
- Price/Book 3.69
|Period||Period Low||Period High||Performance|
| || |
-1.22 (-2.86%)since 11/01/21
| || |
+0.26 (+0.63%)since 09/01/21
| || |
+3.85 (+10.26%)since 12/01/20
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
As a new COVID-19 variant (omnicron) raises concerns worldwide, we think it could be wise to scoop up the shares of quality pharmaceutical stocks GlaxoSmithKline (GSK), Teva Pharmaceutical (TEVA), and...
Glaxo (GSK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.
Canada-based cannabis producer Tilray’s (TLRY) acquisition strategy could drive its long-term growth. However, the company’s shares have fallen in price significantly over the past six months. Uncertainty...
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.
|Glaxosmithkline Plc ADR|
|Vaneck Pharmaceutical ETF|
|Pacer Biothreat Strategy ETF|
|Pacer Global Cash Cows Dividend ETF|
|Pacer Military Times Best Employers ETF|
|Etfmg Treatments Testing and Advancements ETF|
|3rd Resistance Point||42.11|
|2nd Resistance Point||41.93|
|1st Resistance Point||41.65|
|1st Support Level||41.18|
|2nd Support Level||41.00|
|3rd Support Level||40.72|